Literature DB >> 9120536

A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation.

A D McMahon1, J M Evans, G White, F E Murray, M M McGilchrist, D G McDevitt, T M MacDonald.   

Abstract

This cohort study examined the relationship between newly prescribed NSAIDs (none in the previous six months) and upper gastrointestinal hemorrhage and perforation in Tayside, Scotland. Exposure was classified by prescription duration. The study population consisted of the population of Tayside. A Comparator Group was chosen at random (within age and sex strata). Two hundred re-sampled comparator groups were created. Statistical analyses were carried out by Poisson regression (repeated for each of the re-samples). The analyses controlled for age, sex, prior hospitalization for upper gastrointestinal events, prior endoscopy, and the use of ulcer healing drugs. There were 78,191 subjects in the NSAID group, and 78,207 in each of the comparator groups. The increased risk with NSAIDs was only apparent for subjects without a history of upper gastrointestinal events; univariate rate ratio = 2.76 (1.90, 4.01). The final, re-sampled estimate of NSAID risk was rate ratio = 2.48 (1.87, 3.29).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120536     DOI: 10.1016/s0895-4356(96)00361-7

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  10 in total

Review 1.  Use of routine healthcare data in safe and cost-effective drug use.

Authors:  C J Currie; T M MacDonald
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 2.  Record-linkage for pharmacovigilance in Scotland.

Authors:  J M Evans; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

Review 3.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 4.  Rationale for the use of cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs in ankylosing spondylitis: the available evidence.

Authors:  Lars Köehler; Jens G Kuipers; Henning Zeidler
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

5.  Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home.

Authors:  Sebastiano Mercadante; Flavio Fusco; Alessandro Valle; Fabio Fulfaro; Alessandra Casuccio; Stefania Silvestro; Emanuela Donelli
Journal:  Support Care Cancer       Date:  2003-12-12       Impact factor: 3.603

6.  Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.

Authors:  L A García Rodríguez; S Hernández-Díaz; F J de Abajo
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

7.  Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs.

Authors:  Abdulwahed Al-Saeed
Journal:  Oman Med J       Date:  2011-11

Review 8.  Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach.

Authors:  F Richy; O Bruyere; O Ethgen; V Rabenda; G Bouvenot; M Audran; G Herrero-Beaumont; A Moore; R Eliakim; M Haim; J-Y Reginster
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 9.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

Review 10.  Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).

Authors:  Jordi Castellsague; Nuria Riera-Guardia; Brian Calingaert; Cristina Varas-Lorenzo; Annie Fourrier-Reglat; Federica Nicotra; Miriam Sturkenboom; Susana Perez-Gutthann
Journal:  Drug Saf       Date:  2012-12-01       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.